Breast Cancer Collection
The AACR editors are proud to present this selection of impactful journal articles focusing on breast cancer, published from across the AACR journal portfolio.
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, et al. Clinical Cancer Research 2016; DOI:10.1158/10780432.CCR152477. [Published OnlineFirst March 8, 2016].
Tumor evolution inferred by patterns of microrna expression through the course of disease, therapy, and recurrence in breast cancer.
Dadiani M, Moshe NBBB, Shimon-Paluch S, Perry G, Balint N, Marin I, et al. Clinical Cancer Research 2016; DOI:10.1158/10780432.CCR152313. [Published OnlineFirst March 8, 2016].
Synergistic activation of ERα by estrogen and prolactin in breast cancer cells requires tyrosyl phosphorylation of PAK1.
Oladimeji P, Skerl R, Rusch C, Diakonova M. Cancer Research 2016; DOI:10.1158/00085472.CAN151758. [Published OnlineFirst March 4, 2016].
Recombinant Arabidopsis HSP70 sustains cell survival and metastatic potential of breast cancer cells.
Nigro A, Mauro L, Giordano F, Panza S, Iannacone R, Liuzzi GM, et al. Molecular Cancer Therapeutics 2016; DOI:10.1158/15357163.MCT150830. [Published OnlineFirst March 3, 2016].
A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients.
Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, et al. Cancer Prevention Research 2016; DOI:10.1158/19406207.CAPR150311. [Published OnlineFirst February 29, 2016].
The effect of atorvastatin on breast cancer biomarkers in high-risk women.
YongLi J, Rounds T, Crocker AM, Sussman B, Hovey RC, Kingsley F, et al. Cancer Prevention Research 2016; DOI:10.1158/19406207.CAPR150300. [Published OnlineFirst February 23, 2016].
Intermittent high-dose scheduling of AZD8835, a novel selective inhibitor of PI3Kα and PI3Kδ, demonstrates treatment strategies for PIK3CA-dependent breast cancers.
Hudson K, Hancox UJ, Trigwell C, McEwen R, Polanska UM, Nikolaou M, et al. Molecular Cancer Therapeutics 2016; DOI:10.1158/15357163.MCT150687. [Published OnlineFirst February 2, 2016].
What predicts an advanced-stage diagnosis of breast cancer? Sorting out the influence of method of detection, access to care, and biological factors.
Lipscomb J, Fleming ST, Trentham-Dietz A, Kimmick G, Wu XC, Morris CR, et al. Cancer Epidemiology, Biomarkers & Prevention 2016; DOI:10.1158/10559965.EPI150225. [Published OnlineFirst January 27, 2016].
miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors.
Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei MT, et al. Cancer Research 2016; DOI:10.1158/00085472.CAN152038. [Published OnlineFirst January 21, 2016].
Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium.
Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:4708.
Validation of intratumoral T-bet+ lymphoid cells as predictors of disease-free survival in breast cancer.
Mulligan AM, Pinnaduwage P, Tchatchou S, Bull SB, Andrulis IL. Cancer Immunology Research 2016;4:418.
Increased expression of beige/brown adipose markers from host and breast cancer cells influence xenograft formation in mice.
Singh R, Parveen M, Basgen JM, Fazel S, Meshesha MF, Thames EC, et al. Molecular Cancer Research 2016;14:7892.
The CBM complex underwrites NF-κB activation to promote HER2-associated tumor malignancy.
Pan D, Zhu Y, Zhou Z, Wang T, You W, Jiang C, et al. Molecular Cancer Research 2016;14:93102.
Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer.
Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Cancer Immunology Research 2015;3:120717.
Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers.
Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, et al. Cancer Discovery 2015;5:488505.
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, et al. Cancer Discovery 2015;5:7281.